Piramal Pharma Acquires Controlling Stake in Yapan Bio

Piramal Pharma Limited has finalized the acquisition of a controlling stake in Yapan Bio Private Limited, bolstering Piramal's offerings in the biologics sector.

Yapan Bio specializes in process development, characterization, and GMP manufacturing services for vaccines and biologics across Phase I and II clinical trials. Piramal had previously held a stake in Yapan Bio since 2021, enabling the company to offer a broader range of biologics capabilities.

This acquisition expands Piramal Pharma's capacity in the biologics development and manufacturing segments. The move aligns with Piramal's strategy to grow within the expanding pharmaceutical market and provide comprehensive solutions to its clients.

Yapan Bio will continue to operate as a distinct entity within the Piramal Pharma group, expected to complement Piramal's existing manufacturing facilities and research and development operations.